PHST

(redirected from Pharsight Corporation)
AcronymDefinition
PHSTPädagogische Hochschule Steiermark (Graz, Austria school)
PHSTPharsight Corporation (stock symbol)
PHSTPre-Harvest Sprouting Tolerance
PHSTPackaging, Handling, Storage & Transport(ation)
PHSTPacking Handling Storage & Transporting
PHSTPreoperative Hemostatic Screening Tests (surgery)
PHSTProvincial Harmonized Sales Tax (Ontario, Canada)
References in periodicals archive ?
These PD parameters were calculated using the nonlinear WinNonlinA(r) regression program (Pharsight Corporation).
PK-PD analysis was performed using the noncompartmental analysis of Phoenix WinNolin software (version 6.1, Pharsight Corporation, CA, USA).
Pharmacokinetic parameters, including maximum observed serum concentration (C [sub]max ), area under the concentration-time curve with extrapolation to infinity after a single dose (AUC [sub]0-∞ ), clearance (CL), volume of distribution (V), terminal half-life (t[sub]1/2 ), and renal clearance (CLr) were calculated by noncompartmental analysis using Phoenix WinNonlin (version 6.1, Pharsight Corporation, CA, USA).
Software and services company Symyx Technologies Inc (NASDAQ:SMMX) said on Monday that its board of directors has rejected the "best and final" acquisition proposal from Certara Corporation, Tripos International and Pharsight Corporation (together "Certara") and Vector Capital.
In September 2008, it completed the acquisition of Pharsight Corporation. Tripos is a provider of drug discovery informatics products and services; Pharsight is a provider of simulation and modeling software for use in preclinical and clinical settings.
(NAV217) ARTHUR REIDEL - PHARSIGHT CORPORATION (PHST).
Pharsight Corporation (Nasdaq:PHST), Mountain View, Calif., a leading provider of technologies and services that improve the drug development process, has announced results for the third quarter of fiscal 2001.
Pharsight Corporation (Nasdaq:PHST) develops and markets integrated products and services that help pharmaceutical and biotechnology companies improve the drug development process.
Pharsight Corporation, Mountain View, Calif., a provider of software tools, methodologies, and consulting services for the optimization and acceleration of clinical drug development, has signed a strategic partnership with AstraZeneca R&D Molndal, Sweden.
The modified proposal from Certara Corporation, Tripos International and Pharsight Corporation (collectively referred to as "Certara") and Vector Capital ("Vector") concerned an offer to acquire all of the outstanding capital stock of Symyx for USD5.75 per share in cash.
(LAE602) ARTHUR REIDEL, CEO of PHARSIGHT CORPORATION (PHST), describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward.
(JAB215) ARTHUR REIDEL, CEO of PHARSIGHT CORPORATION, describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward.